Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib for Quality of Life in Plaque Psoriasis
NCT05701995Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Started Jan 2023; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05701995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701995.